Morphotek, Inc.

Pfizer Corporation

Genentech, Inc.

Genetech, Inc.

Eisai Inc.

Allogene Therapeutics, Inc.

F. Hoffmann-la Roche Ag

Tao Sai

Nicholas C Nicolaides

Luigi Grasso

Philip M Sass

Marc Berger

Barbra Johnson Sasu

Thomas John Van Blarcom

Siler Panowski

Surabhi Srivatsa Srinivasan

Yan Wu

Wei-Ching Liang

Robert F Kelley

Germaine G Fuh

Daniel Kirchhofer

Menno Van Lookeren Campagne

Chingwei Vivian Lee

Kelly M Loyet

Michael Terry Lipari

Joyce Lai

Roman Galetto

Mathilde Brunnhilde Dusseaux

Niranjana Aditi Nagarajan

Yoon Park

Thomas Charles Pertel

Lauri Diehl

Jennifer Bates

Michael T Lipari

Chingwei V Lee

Daniel K Kirchhofer

The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).

Chimeric antigen receptors targeting CD70

The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.

Antibodies specific for CD70 and their uses

Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.

Antibodies against 4G7-derived chimeric antigen receptors

The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Anti-HtrA1 antibodies and methods of use thereof

Provided herein are antibodies that specifically bind and neutralizeenterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizingenterotoxin B.

High affinity antibodies that neutralizeenterotoxin B

[object Object]

This invention relates to compositions comprising anti-CD83 agonist antibodies and methods of treating autoimmune disorders (such as inflammatory bowel disease) with anti-CD83 agonist antibodies, as well as articles of manufacture comprising anti-CD83 agonist antibodies.

Use of anti-CD83 agonist antibodies for treating autoimmune diseases

This invention provides antibodies that specifically bind and neutralizeenterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizingenterotoxin B.

Growing community of inventors

Foster City, CA, United States of America

Tao Sai